Heinrich-Heine University, Duesseldorf

hhu.de

Total trials

175

Active

50

Phase 3

4

Total enrollment

55,243

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Venetoclax1
Amsacrine1
Ara-C1
Tacrolimus1
Mycophenolate Mofetil1
Adjuvant therapy with one cycle of cisplatin, etoposide and bleomycin1
Autologous, tumor lysate-loaded, mature dendritic cells1
standard therapy1
Anti-CD20 antibody1

Next readouts

  • 2026-01-31
  • 2026-08-31
  • 2027-05
  • 2028-12-31

Top conditions

  • Prostate Cancer8
  • Schizophrenia8
  • Cardiovascular Diseases5
  • Multiple Sclerosis4
  • Healthy3
  • Myelodysplastic Syndromes3
  • Peripheral Arterial Disease3
  • Acute Kidney Injury3

Frequently asked questions about Heinrich-Heine University, Duesseldorf

How many clinical trials does Heinrich-Heine University, Duesseldorf have on ClinicalTrials.gov?
Heinrich-Heine University, Duesseldorf is listed as the lead sponsor on 175 clinical trials in ClinicalTrials.gov, 50 of which are currently active (recruiting, enrolling, or ongoing).
How many of Heinrich-Heine University, Duesseldorf's trials are in Phase 3?
4 of Heinrich-Heine University, Duesseldorf's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Heinrich-Heine University, Duesseldorf focus on?
Heinrich-Heine University, Duesseldorf's most-studied conditions on ClinicalTrials.gov are Prostate Cancer, Schizophrenia, Cardiovascular Diseases, Multiple Sclerosis, Healthy.
When are Heinrich-Heine University, Duesseldorf's next clinical trial readouts?
Heinrich-Heine University, Duesseldorf has 4 upcoming primary-completion readouts tracked here; the soonest is “Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML”, expected around 2026-01-31.